BASi has entered into a Preferred Provider Agreement with G1 Therapeutics for preclinical services, including toxicology, bioanalytical and analytical testing, to support G1’s drug development programs. G1 is a privately held company that develops small molecule therapeutics to protect bone marrow from damage due to chemotherapy or radiation.
BASi’s president, chief executive officer, and chief financial officer, Jacqueline M. Lemke, said, "With our common focus on innovation and scientific excellence, this PPA is a natural arrangement for both of our companies. We are proud that G1 recognizes the ability of BASi’s research team to conduct studies which generate quality and timely data, a critical part of the drug development process."
"BASi has been a valuable partner as we advance our lead clinical candidate toward IND filing and clinical development," said Jay Strum, Ph.D., chief scientific officer and president, G1 Therapeutics. "We look forward to working with BASi to complete a number of pre-clinical activities necessary for the IND filing in 2014."